. Author manuscript; available in PMC: 2016 Sep 1.

Published in final edited form as: Lancet Haematol. 2015 Sep 1;2(9):e376–e383. doi: 10.1016/S2352-3026(15)00127-1

Table 2.

Cytogenetic and molecular response to frontline ponatinib over time

	3 months	6 months	9 months	12 months	18 months
Cytogenetic response
CCyR (%)	45/50 (90%)	43/46 (94%)	37/40 (93%)	26/27 (96%)	21/20 (96%)
PCyR (%)	3/50 (6%)	1/46 (2%)	3/40 (7%)	1/27 (4%)	1/22 (5%)
No CG (%)	2/50 (4%)	2/46 (4%)	0	0	0
Not evaluable	1^* (1)	5^* (3)	11^* (5)	24^* (16)	29^* (20)

Molecular response
MMR (%)	26/50 (52%)	38/46 (83%)	33/40 (83%)	22/27 (82%)	20/22 (91%)
MR^4.5 (%)	2/50 (4%)	23/46 (50%)	51/40 (53%)	15/27 (56%)	16/22 (73%)
No MMR (%)	24/50 (48%)	8/46 (17%)	7/40 (17%)	5/27 (19%)	2/22 (9%)
Not evaluable	1^* (1)	5^* (3)	11^* (5)	24^* (16)	29^* (20)

Responses according to European Leukemia Net (ELN) categories²³
Optimal	48/50 (96%)	43/46 (96%)	..	22/27 (82%)	..
Warning	48/50 (4%)	1/46 (2%)	..	4/27 (15%)	..
Failure	..	1/46 (2%)	..	1/27 (3%)	..

CCyR=complete cytogenetic response. PCyR=partial cytogenetic response. CG=cytogenetic response. MMR=major molecular response. MR^4.5=deep molecular response.

All patients who were not evaluable came off study due to US Food and Drug Administration warning (indicated in parentheses) or adverse events.